Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics is in a transition phase where it is working to fully recover from unexpected provider attrition and implementing cost-saving initiatives while also strategically expanding its channel and offerings. With strong revenue growth of 16% and a potential for improved operational efficiency and continued revenue growth in 2026, this company has potential for high returns. However, risks include low visibility on revenues and margins, potential dilution from financing, and some uncertainties regarding the revenue ramp. Overall, we maintain a positive outlook and reiterate a Buy rating, adjusting our 12-month price target to $3.00 (from $7.00) to reflect a higher share count.

Vivos Therapeutics is facing a variety of risks including liquidity concerns, potential regulatory roadblocks, competition within the sleep apnea treatment market, and dependence on consumer attitudes. As evidenced in recent financing activities and increased share count, the company may struggle to achieve profitability without further capital raises. While their technology shows promise and may provide a better alternative to traditional sleep apnea treatments, potential barriers to widespread adoption and expansion of their sleep-center model pose challenges in achieving significant revenue growth. As a result, we have a negative outlook on Vivos Therapeutics' stock.